Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Enterprise Value (2016 - 2025)

Dexcom (DXCM) has disclosed Enterprise Value for 15 consecutive years, with -$134.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Enterprise Value rose 76.3% to -$134.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$134.2 million, a 76.3% increase, with the full-year FY2024 number at -$134.2 million, up 76.3% from a year prior.
  • Enterprise Value was -$134.2 million for Q4 2024 at Dexcom, up from -$621.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$134.2 million in Q4 2024 to a low of -$1.4 billion in Q3 2021.
  • A 5-year average of -$768.0 million and a median of -$707.0 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 118.64% in 2021, then skyrocketed 76.3% in 2024.
  • Dexcom's Enterprise Value stood at -$817.6 million in 2020, then decreased by 28.74% to -$1.1 billion in 2021, then surged by 38.98% to -$642.3 million in 2022, then increased by 11.83% to -$566.3 million in 2023, then surged by 76.3% to -$134.2 million in 2024.
  • Per Business Quant, the three most recent readings for DXCM's Enterprise Value are -$134.2 million (Q4 2024), -$621.2 million (Q3 2024), and -$939.2 million (Q2 2024).